Viridian Therapeutics, Inc.

NasdaqCM VRDN

Viridian Therapeutics, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2024: USD 0.01

Viridian Therapeutics, Inc. Revenue Per Share is USD 0.01 for the Trailing 12 Months (TTM) ending September 30, 2024, a -38.73% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.
  • Viridian Therapeutics, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 0.01, a -89.26% change year over year.
  • Viridian Therapeutics, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 0.08, a -79.93% change year over year.
  • Viridian Therapeutics, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 0.38, a -37.08% change year over year.
  • Viridian Therapeutics, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 0.60, a -69.34% change year over year.
Key data
Date Revenue Per Share Dividend Per Share Free Cash Flow Per Share Return on Assets (ROA)
Market news
NasdaqCM: VRDN

Viridian Therapeutics, Inc.

CEO Mr. Stephen F. Mahoney J.D., MBA
IPO Date June 18, 2014
Location United States
Headquarters 221 Crescent Street
Employees 94
Sector Health Care
Industries
Biotechnology Clinical Trials Pharmaceuticals
Description

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.

Similar companies

MRUS

Merus N.V.

USD 39.01

-3.56%

ACLX

Arcellx, Inc.

USD 64.65

-4.02%

SNDX

Syndax Pharmaceuticals, Inc.

USD 12.60

-1.56%

INZY

Inozyme Pharma, Inc.

USD 1.51

-12.21%

RVMD

Revolution Medicines, Inc.

USD 39.83

-6.44%

KURA

Kura Oncology, Inc.

USD 7.26

0.28%

ETNB

89bio, Inc.

USD 6.28

-0.47%

TERN

Terns Pharmaceuticals, Inc.

USD 4.57

-4.79%

PTGX

Protagonist Therapeutics, Inc.

USD 36.67

-1.26%

CRNX

Crinetics Pharmaceuticals, Inc.

USD 35.62

-8.62%

PLRX

Pliant Therapeutics, Inc.

USD 11.24

-4.50%

PCVX

Vaxcyte, Inc.

USD 78.14

-3.73%

GPCR

Structure Therapeutics Inc.

USD 25.38

0.87%

CYTK

Cytokinetics, Incorporated

USD 45.23

-3.17%

REPL

Replimune Group, Inc.

USD 10.49

-3.67%

BPMC

Blueprint Medicines Corporation

USD 102.56

-0.77%

NUVL

Nuvalent, Inc.

USD 72.39

0.74%

StockViz Staff

January 15, 2025

Any question? Send us an email